|
|
Sclavo peptide |
|
Vaxjo ID |
58 |
|
Vaccine Adjuvant Name |
Sclavo peptide |
|
Alternative Names |
IL-1β 163-171 peptide |
|
Adjuvant VO ID |
VO_0001313
|
|
Description |
Sclavo peptide acts as a primary adjuvant and is active either when administered separately from antigen, or admixed with antigen, or physically linked to antigen. Routes of administration: i.v., i.p., c.c., p.o. Marked adjuvant activity is also observed upon injection of the coding sequence in plasmid DNA vaccines (Vogel and Powell, 1995). |
|
Stage of Development |
Research |
|
Components |
IL-1β 163-171 peptide (Vogel and Powell, 1995) |
|
Structure |
VQGEESNDK • HCl |
|
Molecular Weight |
1 kD |
|
Appearance |
White, odorless powder. |
|
Storage |
Stored lyophilized peptide dry at -20° C. Stable also at room temperature. The concentrated solution can be stored in siliconized glass at 4° C for at least 2-3 months. Do not freeze (Vogel and Powell, 1995). |
|
Preparation |
From human IL-1b amino acid sequence. Obtained by solid phase synthesis, purified by HPLC and ion exchanged to the HCI salt (Vogel and Powell, 1995). |
|
Function |
It enhances immune response to T-dependent and T-independent antigens. Active also in increasing secondary responses. Active as adjuvant for a tumor vaccine. Antitumor activity through recruitment of host immune response (Vogel and Powell, 1995). |
|
Safety |
No toxicity in mice when given i.v. as a bolus up to 100 mg/kg (Vogel and Powell, 1995). |
| References |
Vogel and Powell, 1995: Vogel FR, Powell MF. A compendium of vaccine adjuvants and excipients. Pharmaceutical biotechnology. 1995; 6; 141-228. [PubMed: 7551218].
|
|
